Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,790,000 shares, an increase of 72.1% from the February 13th total of 1,040,000 shares. Based on an average trading volume of 576,100 shares, the days-to-cover ratio is presently 3.1 days. Approximately 5.6% of the shares of the company are sold short.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on LUCD. Ascendiant Capital Markets dropped their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a report on Monday, December 9th. Cantor Fitzgerald dropped their price objective on shares of Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $3.63.
View Our Latest Report on Lucid Diagnostics
Institutional Investors Weigh In On Lucid Diagnostics
Lucid Diagnostics Trading Up 8.6 %
NASDAQ LUCD opened at $1.39 on Friday. The company’s 50 day moving average is $1.14 and its two-hundred day moving average is $0.96. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.63. The stock has a market cap of $82.49 million, a price-to-earnings ratio of -1.22 and a beta of 1.34.
About Lucid Diagnostics
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Featured Articles
- Five stocks we like better than Lucid Diagnostics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- What is a support level?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.